Sight Sciences is expected to report Q3 2026 revenue of $23.51 million and a narrowed loss per share of $0.12, with the current $9.32 stock price trading below the consensus analyst target of $10.17.
Investors are primarily focused on the commercial execution and early adoption of the OMNI Ultra Surgical System following its official launch at the American Academy of Ophthalmology meeting.
The market is also monitoring the expansion of the Interventional Dry Eye segment, which is projected to reach approximately $3 million in quarterly revenue. Recent reimbursement wins, such as the addition of 25 million covered lives from Aetna, provide significant tailwinds for the company's surgical glaucoma and dry eye portfolios.